Whalesbook
Dekho, Lupin ne finance year 2026 ke Q4 mein ekdum jhakas results diye hain! Revenue 31.9% badh kar ₹7,474.66 Crore ho gaya, aur profit before tax toh 115.2% tez ho kar ₹1,928.00 Crore tak pahunch gaya! Net profit bhi 87.8% badh kar ₹1,413.07 Crore. Poore saal ki baat karein toh revenue 23.1% badh kar ₹27,958.03 Crore aur profit 62.8% badh kar ₹5,182.89 Crore ho gaya, Q4 mein per share earning (EPS) thi ₹31.96. Par is sab ke baad bhi stock May 8, 2026 ko neeche gir gaya. Lagta hai investors ne jo news thi use already price in kar liya tha ya phir valuation ko lekar kuch chinta hai.
Growth Drivers and Valuation Checks
Is dhamakedar performance ka sabse bada reason hai US market, jahan Q4FY26 mein sales 56.9% bhaagi aur ₹3,398.7 Crore tak pahunch gayi. India mein bhi company ne accha perform kiya. Plus, Lupin ne VISUfarma B.V. aur Renascience Pharma Limited ko acquire karke apna global reach aur mazboot kiya hai. Company ki financial position bhi acchi hai, total assets ₹38,364.83 Crore aur equity ₹22,513.37 Crore ho gayi March 2026 tak. Unke paas cash bhi accha hai, Net Debt ₹ -46,358 Mn. Lupin ki market cap around ₹1.11-1.12 trillion hai, aur trailing P/E ratio 23.4x to 23.9x ke aas paas hai, jo pharma sector mein Cipla Ltd. (23x) ke barabar aur Sun Pharmaceutical Industries Ltd. (36x), Divi's Laboratories Ltd. (69x) se kam hai. Stock pichhle saal S&P BSE 100 Index ko 10% se beat kar chuka hai aur 200-day moving average se upar chal raha hai.
Concerns Amidst Strong Results: Put Options and Analyst Targets
Abhi bhi kuch chinta ki baatein hain. Stock itne acche results ke baad bhi neeche kyun gira? Shayad market ko yeh sab pehle se pata tha ya valuation zyada lag raha hai. Aur haan, May 7-8, 2026 ko put option trading mein kaafi gadbad dikhi hai, strike prices ₹2,400 aur ₹2,300 par. Iska matlab traders expecting hain ki stock shayad neeche girega. Analysts toh zyada tar 'Buy' bol rahe hain (40 mein se 28), par unka average target price ₹2,434.86 hai, jo current price se sirf 0.4% upar hai. Matlb zyada bada jump expect nahi hai. Delivery volumes bhi 5-day average se 27.21% kam hain.
Lupin's Path Forward: Growth and Shareholder Returns
Lupin ka aim hai technology, execution aur smooth operations se performance aur tez karna. Woh specialty products, complex generics aur biosimilars par focus kar rahe hain. Shareholders ko bhi company ne treat diya hai, ₹18 per share ka final dividend propose kiya hai. Ab dekhte hain company kaise manage karti hai competition aur acquisitions ko.